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Pulmonary hypertension (PH) is a progressive and devas-
tating disease of various causes that is associated with
structural and functional disorder and inappropriately
increased pressure of pulmonary small- to medium-sized
vasculature. Extensive pulmonary vascular remodeling with
narrowing lumen is well characterized in all forms of PH,
which is hemodynamically deﬁned by a mean pulmonary
artery pressure exceeding 25 mmHg at rest (Schermuly
et al., 2011; Mehari et al., 2014). The morbidity and mortality
of PH continues to increase due to no cure (Mehari et al.,
2014); however, our understanding of the mechanism and
therapeutics underlying PH remains far from complete.
There are many competing hypotheses for how PH develops
in a genetic or sporadic way (Schermuly et al., 2011). One of
them is that the endothelial-to-mesenchymal transition
(EndMT) could be implicated in initiation and progression of
human PH (Arciniegas et al., 2007). Notably, this point is
further emphasized by two recent papers, which provide
direct evidence linking EndMT to PH (Good et al., 2015;
Ranchoux et al., 2015).
Vascular remodeling of intimal, medial, and adventitial
hypertrophy in PH roughly involves endothelium, smooth
muscle, and ﬁbroblasts (Schermuly et al., 2011). Although
pulmonary vasculature in PH is thought to undergo a series
of structure change events with a complex multifactorial
etiology, endothelial cells seem to play a central role in this
process in view of the following four major reasons. First, the
common plexiform lesions in the vessels of patients with
PH generally result from excessive endothelial cell prolifer-
ation. Second, endothelial cells act with quite widespread
autocrine and paracrine effects via secretion of numer-
ous cell signaling effectors including, but certainly not limited
to, nitric oxide, endothelin-1, and serotonin. Third, impaired
semipermeable barrier of the pulmonary endothelial lining
due to endothelial injuries renders the underlying intersti-
tial cells susceptible to diverse blood-borne factors
(Budhiraja et al., 2004). Last, germline loss-of-function bone
morphogenic protein receptor type 2 (BMPR2) mutations
have been signiﬁcantly linked to the etiology of familial and
idiopathic primary pulmonary hypertension (International
et al., 2000; Austin and Loyd, 2014). More importantly,
BMPR2 is predominantly expressed in endothelium and
tightly controls the permeability of the pulmonary artery
endothelial wall (Atkinson et al., 2002; Burton et al., 2011).
EndMT is characterized by the acquisition of mesenchy-
mal- and stem-cell-like properties in endothelium subjected to
intrinsic or extrinsic cues and functions as a critical source of
ﬁbroblasts in various physiological and pathological settings
encompassing heart development, tumor progression, and
ﬁbrosis (Lin et al., 2012; Yu et al., 2014). One such notorious
ﬁbrosis target organ is lung. Reduced ﬁbrinolytic activity and
thereby elevated cellular ﬁbronectin concentration have been
demonstrated in the lung vessels of monocrotaline-induced
rat PHmodel (Schultze andRoth, 1993; Schultze et al., 1996).
Increased collagen deposition is capable of decreasing the
distensibility of hypertensive pulmonary arteries (Tozzi et al.,
1994). As mentioned earlier, even dysregulation of the intra-
cellular cytoskeleton network causes altered permeability and
morphology of pulmonary endothelium (Dudek and Garcia,
2001). Subsequently, Arciniegas and colleagues observed
EndMT in pulmonary artery development of chicken embryos
in vivo and in vitro (Arciniegas et al., 2005). In addition, myo-
cardin promotes the transdifferentiation of pulmonary arterio-
lar endothelial cells into smooth muscle-like cells in hypoxia-
induced rat PH model and porcine pulmonary artery
endothelial cells (Zhu et al., 2006). A prior study showed a
spontaneous and transforming growth factor β (TGF-β)-in-
duced EndMT in pulmonary endothelial cells isolated from
caveolin-1 knockout mice compared to their wild-type litter-
mates (Li et al., 2013). Moreover, the precisely orchestrated
EndMT contributes to bleomycin- and radiation-induced pul-
monary ﬁbrosis (Hashimoto et al., 2010; Choi et al., 2015). As
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progressive pulmonary ﬁbrosis can lead to pulmonary hyper-
tension (Rockey et al., 2015), it will be of considerable interest
to askwhetherEndMTparticipates in the regulatory network of
human PH and, if so, what is the exact role of EndMT in the
development of PH?
A key step towards answering these questions has been
made by two intriguing studies (Good et al., 2015; Ranchoux
et al., 2015) (Fig. 1). As some may recall, Qiao and colleagues
took advantage of mice that underwent left pneumonectomy
andmonocrotaline pyrrole injection to establish amousemodel
of PH. Endothelial lineage tracing analyses in this PH mouse
model reveals that endothelial cells in the pulmonary neointima
have detectable smooth muscle gene expression. Likewise,
concurrent expression of endothelial cell and smooth muscle
markers occurs in human pulmonary arterial hypertension
neointimal lesions (Qiao et al., 2014). Consistent with these
observations, Good et al. determined the presence of EndMT
by assessing the colocalization of vonWillebrand factor and α-
smooth muscle actin (α-SMA) in the pulmonary endothelium
from the hypoxia/SU5416 preclinical murine pulmonary artery
hypertension (PAH) model and systemic sclerosis-associated-
PAH (SSc-PAH) patients. Furthermore, a panel of functional
assays in vitro lends further support to the notion that EndMT is
a bona ﬁde mechanism underlying the pathogenesis of PH
(Good et al., 2015). TGF-β has been delineated as a major
inducer of EndMT (van Meeteren and ten Dijke, 2012). Nev-
ertheless, utilizing the single reagent TGF-β to galvanize tran-
scription program switching in the EndMTof human pulmonary
microvascular endothelial cells seems to require three weeks
and several passages (Reynolds et al., 2012). Using a cocktail
of TGF-β and inﬂammatory cytokins tumor necrosis factor α
(TNFα) and interleukin 1β (IL-1β) previously described for
induction of EndMT in human intestinal microvascular
endothelial cells (Rieder et al., 2011), Good et al. obtained the
induced EndMT (I-EndMT) cells derived from human pul-
monaryarteryendothelial cells in vitro inamoreefﬁcient fashion
(Good et al., 2015). These I-EndMTcells secrete high levels of





















Figure 1. The role of endothelial-to-mesenchymal transition (EndMT) at roughly early (A) and late (B) stages in the
pathogenesis of pulmonary hypertension. (A) Genetic and/or microenvironmental insults-induced EC injuries trigger EndMT in
pulmonary vasculature. (B) Activated EndMTcells secrete proinﬂammatory cytokins to potentially stimulate VSMC and/or SM-like cell
proliferation and inhibit these cell apoptosis, leading to pulmonary hypertension. Abbreviations: EC, endothelial cell; VSMC, vascular
smooth muscle cell; SM-like, smooth muscle-like; IL-6, interleukin-6; IL-8, interleukin-8; TNFα, tumor necrosis factor α.
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exhibit a similar proinﬂammatory phenotype in patients with
human lung ﬁbroblasts SSc-PAH. Next, it was found that the
endothelial barrier integrity is signiﬁcantly compromised in
I-EndMT cells, reminiscent of the features in PH endothelium
(Budhiraja et al., 2004; Good et al., 2015).
Writing in Circulation at nearly the same time, Ranchoux
et al. reported that analysis of endothelial cell-cell junction, and
endothelial and subendothelial cell phenotype in intimal and
plexiform lesions from PAH lungs relative to control non-tumor
lung specimens, was carried out using unambiguous
endothelial (CD31, CD34, VE-cadherin) and mesenchymal α-
SMA markers. Combined with this analysis result, the protein
and mRNA expression patterns consolidate the notion of a key
role of EndMT in PH pathology (Ranchoux et al., 2015). Addi-
tionally, a unique and reﬁned morphological signature in plex-
ogenic pulmonary arteriopathy has been identiﬁed thanks to
pioneering research efforts (Smith and Heath, 1979; Weibel,
2012). Remarkably, Ranchoux and co-workers applied trans-
mission electron microscopy, and correlative light and electron
microscopy, providing unequivocal ultrastructural-level evi-
dence of ongoing dynamic EndMT in PH samples. Next, the
EndMT was examined in the context of conventional
monocrotaline and SuHx mouse PH models and the novel
BMPR2 deﬁcient rat PH model. Indeed, the in vivo EndMT
characteristics in thesemousemodelsare comparable to those
in human PH tissues. Excitingly, partial rescue of EndMT-re-
lated gene expression and phenotypes has been achieved by
rapamycin (Ranchoux et al., 2015).
The headline ﬁnding of these two studies is that the concept
of EndMT in PH has been initially proposed on the basis of
compelling experimental proofs (Good et al., 2015; Ranchoux
et al., 2015). This discovery opens a new therapeutic window for
suppressing or even reversing the pathogenic progression in
certain common, but genetically deﬁned, subtype of human PH.
Each pulmonary endothelial cell in potential or current patients
with PH decides whether its next action is to be EndMTor not to
be (with apologies to pre-eminent English dramatist William
Shakespeare for scrambling the immortal opening phase in his
play Hamlet). In the broad landscape, it will be imperative to
determine how the EndMT process is orchestrated, and what its
context dependencies may be. Future advances in under-
standing the distinct stage-speciﬁc EndMT events and the
druggability of EndMTwill require a gene expression proﬁle and
more functional analyses to unravel themolecularmechanism in
a tempo-spatialmanner.Finally, thesestudiesoffer thepossibility
of EndMT as a promising pharmaceutical target in human PH,
which warrants further investigations.
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